Patents by Inventor Beatrice S. Knudsen

Beatrice S. Knudsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
    Patent number: 8309315
    Abstract: In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided.
    Type: Grant
    Filed: August 25, 2008
    Date of Patent: November 13, 2012
    Assignees: Van Andel Research Institute, Fred Hutchinson Cancer Research Center
    Inventors: Boliang Cao, George F. Vande Woude, Beatrice S. Knudsen, Ping Xu Zhao
  • Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
    Patent number: 7892770
    Abstract: In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: February 22, 2011
    Assignees: Van Andel Research Institute, Fred Hutchinson Cancer Research Center
    Inventors: Boliang Cao (Brian), George F. Vande Woude, Beatrice S. Knudsen
  • MONOCLONAL ANTIBODY WHICH BINDS MET IN FORMALIN-FIXED AND PARAFFIN-EMBEDDED TISSUES AND RELATED METHODS
    Publication number: 20100285504
    Abstract: In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided.
    Type: Application
    Filed: August 25, 2008
    Publication date: November 11, 2010
    Applicant: VAN ANDEL RESEARCH INSTITUTE
    Inventors: Boliang Cao, George F. Vande Woude, Beatrice S. Knudsen, Ping Xu Zhao
  • Monoclonal Antibody Which Binds Met In Formalin-Fixed and Paraffin-Embedded Tissues and Related Methods
    Publication number: 20090053737
    Abstract: In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided.
    Type: Application
    Filed: August 24, 2007
    Publication date: February 26, 2009
    Inventors: Boliang Cao (Brian), George F. Vande Woude, Beatrice S. Knudsen
  • Peptides specific for the first Crk-SH3 domain
    Patent number: 5888763
    Abstract: The present invention relates to regulation and control of cellular processes by SH3-domain binding proteins and peptides. In particular, the invention provides a consensus sequence of a peptide that shows high specificity and affinity for the first SH3 domain of cellular Crk. In specific examples, a number of peptides that contain the consensus are shown to bind c-Crk specifically. The molecular basis for this specificity is examined by crystallography.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: March 30, 1999
    Assignee: The Rockefeller University
    Inventors: Hidesaburo Hanafusa, Beatrice S. Knudsen, Stephan M. Feller, John Kuriyan, Xiaodong Wu, Jie Zheng, David Cowburn